Journal of Gastrointestinal Cancer

, Volume 43, Issue 4, pp 562–569 | Cite as

A Phase II Study of Capecitabine, Oxaliplatin, and Cetuximab with or Without Bevacizumab as Frontline Therapy for Metastatic Colorectal Cancer. A Fox Chase Extramural Research Study

  • Efrat Dotan
  • Neal J. Meropol
  • Barbara Burtness
  • Crystal S. Denlinger
  • James Lee
  • David Mintzer
  • Fang Zhu
  • Karen Ruth
  • Holly Tuttle
  • Judi Sylvester
  • Steven J. Cohen
Original Research



Dual inhibition of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) demonstrated initial promise in clinical trials. This phase II study tested the efficacy and safety of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as first-line treatment for metastatic colorectal cancer patients.


Patients were randomized to receive capecitabine 850 mg/m2 PO twice daily for 14 days, oxaliplatin 130 mg/m2 IV day 1, and cetuximab 400 mg/m2 IV loading dose followed by 250 mg/m2 IV days 1, 8, and 15 with (Arm A) or without (Arm B) bevacizumab 7.5 mg/kg IV day 1 every 21 days. Tumor samples were collected and retrospectively analyzed for KRAS mutation status. The primary endpoint was response rate, with time to progression (TTP) and overall survival (OS) as secondary objectives.


Twenty-three patients (12 in Arm A, 11 in Arm B) were enrolled onto the study. Median follow-up was 25.9 months. Both treatments were well tolerated, with expected higher rates of grade 1/2 hypertension and bleeding in Arm A. The overall response rate was 54% (36.4% in Arm A and 72.7% in Arm B). Median time to progression was 8.7 months in Arm A and 14.4 months in Arm B. The median survival was 18.0 months in Arm A and 42.5 months in Arm B. The study was prematurely terminated after other studies reported inferior outcomes with dual antibody therapy.


Although terminated early, the study supports the detrimental effect of combining VEGF and EGFR inhibition in metastatic colorectal cancer.


Metastatic colon cancer Vascular endothelial growth factor (VEGF) Epidermal growth factor receptor (EGFR) 


Conflict of Interest

Dr. Barbara Burtness receives research funding from Genentech.

Dr. Steven Cohen receives research funding from Genentech and BMS.

All other authors state that they have no relevant conflicts of interest.


  1. 1.
    Goldberg RM, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004;22(1):23–30.PubMedCrossRefGoogle Scholar
  2. 2.
    Cassidy J, et al. XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol. 2004;22(11):2084–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Van Cutsem E, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol. 2001;19(21):4097–106.PubMedGoogle Scholar
  4. 4.
    Hoff PM, et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. J Clin Oncol. 2001;19(8):2282–92.PubMedGoogle Scholar
  5. 5.
    Cassidy J, et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol. 2008;26(12):2006–12.PubMedCrossRefGoogle Scholar
  6. 6.
    Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol. 2006;33(5 Suppl 10):S26–34.PubMedCrossRefGoogle Scholar
  7. 7.
    Giantonio BJ, et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25(12):1539–44.PubMedCrossRefGoogle Scholar
  8. 8.
    Saltz LB, et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Saltz LB, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol. 2004;22(7):1201–8.PubMedCrossRefGoogle Scholar
  10. 10.
    Cunningham D, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351(4):337–45.PubMedCrossRefGoogle Scholar
  11. 11.
    Tabernero J, et al. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2007;25(33):5225–32.PubMedCrossRefGoogle Scholar
  12. 12.
    Bokemeyer C et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol. 2011;22(7):1535–46.Google Scholar
  13. 13.
    Douillard JY, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010;28(31):4697–705.PubMedCrossRefGoogle Scholar
  14. 14.
    Van Cutsem E, et al. A meta-analysis of the CRYSTAL and OPUS studies combining cetuximab with chemotherapy (CT) as 1st-line treatment for patients (pts) with metastatic colorectal cancer (mCRC): results according to KRAS and BRAF mutation status. Eur J Cancer Suppl. 2009;7(2):345. Abstract # P-6077.CrossRefGoogle Scholar
  15. 15.
    Karapetis CS, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359(17):1757–65.PubMedCrossRefGoogle Scholar
  16. 16.
    Ciardiello F, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res. 2000;6(9):3739–47.PubMedGoogle Scholar
  17. 17.
    Saltz LB, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol. 2007;25(29):4557–61.PubMedCrossRefGoogle Scholar
  18. 18.
    Therasse P. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.PubMedCrossRefGoogle Scholar
  19. 19.
    Tol J, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med. 2009;360(6):563–72.PubMedCrossRefGoogle Scholar
  20. 20.
    Hecht JR, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009;27(5):672–80.PubMedCrossRefGoogle Scholar
  21. 21.
    Wong NS, et al. A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer. Anticancer Res. 2011;31(1):255–61.PubMedGoogle Scholar
  22. 22.
    Sanoff HK, et al. Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008;26(35):5721–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Punt CJ, Tol J. More is less—combining targeted therapies in metastatic colorectal cancer. Nat Rev Clin Oncol. 2009;6(12):731–3.PubMedCrossRefGoogle Scholar
  24. 24.
    Marshall JL. Vascular endothelial growth factor plus epidermal growth factor receptor dual targeted therapy in metastatic colorectal cancer: synergy or antagonism? J Oncol. 2009;2009:937305.PubMedCrossRefGoogle Scholar
  25. 25.
    Selvakumaran M, et al. Antitumor effect of the angiogenesis inhibitor bevacizumab is dependent on susceptibility of tumors to hypoxia-induced apoptosis. Biochem Pharmacol. 2008;75(3):627–38.PubMedCrossRefGoogle Scholar
  26. 26.
    Li X, et al. Requirement of hypoxia-inducible factor-1alpha down-regulation in mediating the antitumor activity of the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Mol Cancer Ther. 2008;7(5):1207–17.PubMedCrossRefGoogle Scholar
  27. 27.
    Zeng M, et al. Hypoxia activates the K-ras proto-oncogene to stimulate angiogenesis and inhibit apoptosis in colon cancer cells. PLoS One. 2010;5(6):e10966.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  • Efrat Dotan
    • 1
  • Neal J. Meropol
    • 2
  • Barbara Burtness
    • 1
  • Crystal S. Denlinger
    • 1
  • James Lee
    • 3
  • David Mintzer
    • 4
  • Fang Zhu
    • 5
  • Karen Ruth
    • 5
  • Holly Tuttle
    • 6
  • Judi Sylvester
    • 6
  • Steven J. Cohen
    • 1
  1. 1.Department of Medical OncologyFox Chase Cancer CenterPhiladelphiaUSA
  2. 2.University Hospitals Seidman Cancer CenterCase Western Reserve UniversityClevelandUSA
  3. 3.Hematology Oncology Associates, SJMt. HollyUSA
  4. 4.Pennsylvania Oncology Hematology AssociatesPhiladelphiaUSA
  5. 5.Department of Biostatistics and BioinformaticsFox Chase Cancer CenterPhiladelphiaUSA
  6. 6.Extramural Research ProgramFox Chase Cancer CenterPhiladelphiaUSA

Personalised recommendations